Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use

April 2003

Allergan is introducing Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use.

Restasis is approved for patients with chronic dry eye disease...also called keratoconjunctivitis sicca.

Chronic dry eye disease is caused by chronic inflammation, aging, or autoimmune disorders such as Sjögren's syndrome.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote